Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature

Xu,Mingfang; Huang,Huan; Xiong,Yanli; Peng,Bo; Zhou,Zejun; Wang,Dong; Yang,Xueqin

doi:10.3892/ol.2014.2087

Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature

Authors:
- Mingfang Xu
- Huan Huang
- Yanli Xiong
- Bo Peng
- Zejun Zhou
- Dong Wang
- Xueqin Yang
View Affiliations

Affiliations: Cancer Center, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2087
Pages: 291-294

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For the majority of inoperable esophageal cancer cases, chemoradiotherapy is the most suitable treatment option. Cetuximab may provide certain benefits, however, this can be an expensive therapy. Additionally, stereotactic body radiation therapy (SBRT) is typically contraindicated for esophageal cancer due to the potential for esophageal perforation and stenosis. The use of combined chemotherapy plus endostar with sequential SBRT for the treatment of esophageal squamous cancer has not been reported. In the current study, the case of a 71‑year‑old female with esophageal squamous cancer diagnosed 2 years prior is presented. Surgery and four cycles of cisplatin plus 5‑fluorouracil chemotherapy had been administered. The patient showed recurrence at the paratracheal lymph node, exhibited severe dyspnea (grade III) and required a semi‑liquid diet. Four cycles of the docetaxel, 5‑fluorouracil and nedaplatin regimen plus endostar (3 mg; days 1‑14; intravenously) with sequential SBRT (3300 cGy in 10 fractions) was administered. Following treatment, the symptoms of the patient completely disappeared, and objective efficacy evaluation indicated complete remission. At the time of writing, the patient is living without discomfort and the progression‑free survival is >8 months. In conclusion, the present case indicates that combined treatment of chemotherapy and endostar with sequential stereotactic radiotherapy is a safe and effective option for the management of esophageal cancer.

View Figures

View References

1	Karaosmanoğlu AD and Blake MA: Applications of PET-CT in patients with esophageal cancer. Diagn Interv Radiol. 18:171–182. 2012.
2	Koshy M, Esiashvilli N, Landry JC, et al: Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist. 9:137–146. 2004.
3	Tytgat GN, Bartelink H, Bernards R, et al: Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus. 17:10–26. 2004.
4	Huang J, Zhou Y, Zhang H, et al: A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 30:3432013.
5	Emi M, Hihara J, Hamai Y, et al: Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol. 69:1499–1505. 2012.
6	Idelevich E, Kashtan H, Klein Y, et al: Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie. 35:427–431. 2012.
7	Lorenzen S, Schuster T, Porschen R, et al: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 20:1667–1673. 2009.
8	Vosmik M, Petera J, Sirak I, et al: Technological advances in radiotherapy for esophageal cancer. World J Gastroenterol. 16:5555–5564. 2010.
9	Gao XS: Considerations of treatment standardization from the procession of NCCN guideline of esophageal cancer. Chin J Cancer. 29:860–864. 2010.
10	Katsoulis IE, Karoon A, Mylvaganam S and Livingstone JI: Endoscopic palliation of malignant dysphagia: a challenging task in inoperable oesophageal cancer. World J Surg Oncol. 4:382006.
11	Wong SK, Chiu PW, Leung SF, et al: Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. Ann Surg Oncol. 15:576–582. 2008.
12	Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999.
13	Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002.
14	Lin SH, Wang L, Myles B, et al: Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 84:1078–1085. 2012.
15	Nutting CM, Bedford JL, Cosgrove VP, et al: A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol. 61:157–163. 2001.
16	Mundt AJ, Mell LK and Roeske JC: Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 56:1354–1360. 2003.
17	Uy NW, Woo SY, Teh BS, et al: Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys. 53:1265–1270. 2003.
18	Vicini FA, Sharpe M, Kestin L, et al: Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 54:1336–1344. 2002.
19	Homs MY, Eijkenboom WM, Coen VL, et al: High dose rate brachytherapy for the palliation of malignant dysphagia. Radiother Oncol. 66:327–332. 2003.
20	Homs MY, Steyerberg EW, Eijkenboom WM, et al: Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 364:1497–1504. 2004.
21	Russo JK and Rosen L: TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: a case report. Tumori. 97:406–410. 2011.
22	O’Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997.
23	Rong B, Yang S, Li W, et al: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 10:1702012.
24	Zhou J, Wang L, Xu X, et al: Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett. 4:976–980. 2012.
25	Jin F, Ji H, Jia C, et al: Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116. PLoS One. 7:e471612012.
26	Chang L, Guo F, Lv Y, et al: The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice. Mol Biol Rep. 40:669–673. 2013.
27	Zhong Z, Gu X, Zhang Z, et al: Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol. 85:e1104–e1109. 2012.